汉森制药(002412) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥254,032,546.62, representing a 1.54% increase compared to ¥250,177,963.58 in the same period last year[4] - Net profit attributable to shareholders was ¥58,264,674.17, up 5.81% from ¥55,067,482.18 year-on-year[4] - Total operating revenue for Q1 2024 was CNY 254,032,546.62, a 1.5% increase from CNY 250,177,963.58 in Q1 2023[20] - Net profit for Q1 2024 was CNY 58,264,674.17, representing a 4.0% increase compared to CNY 55,067,482.18 in Q1 2023[21] - Basic and diluted earnings per share increased to CNY 0.1158 from CNY 0.1094 year-over-year[22] Cash Flow - The net cash flow from operating activities decreased significantly by 70.89%, amounting to ¥20,503,807.95 compared to ¥70,447,112.49 in the previous year[4] - Cash flow from operating activities generated a net amount of CNY 20,503,807.95, a significant decrease from CNY 70,447,112.49 in the previous year[22] - The net cash flow from investment activities was 1,329,594.94, a significant improvement compared to the negative cash flow of 73,944,830.71 in the previous year[23] - The net cash flow from financing activities was 1,831,534.64, down from 2,045,917.55 in the same period last year[23] - The net increase in cash and cash equivalents for the quarter was 23,664,937.53, a recovery from the negative change of -1,451,800.67 in the same quarter last year[23] Assets and Liabilities - Total assets at the end of the reporting period increased by 2.30% to ¥2,390,145,792.92 from ¥2,336,488,623.93 at the end of the previous year[4] - Total liabilities amounted to CNY 362,718,320.00, a decrease from CNY 373,459,685.26 in the previous year[18] - The company's total current liabilities decreased to ¥342,596,533.69 from ¥355,424,606.90, a reduction of about 3.6%[17] - The total non-current assets stood at ¥1,441,761,018.84, slightly up from ¥1,440,414,236.14, showing a marginal increase[17] Shareholder Information - The company's total equity attributable to shareholders increased by 3.28% to ¥2,027,427,472.92 from ¥1,963,028,938.67 at the end of the previous year[4] - Total equity attributable to shareholders increased to CNY 2,027,427,472.92 from CNY 1,963,028,938.67 year-over-year[18] - The total number of common shareholders at the end of the reporting period is 28,376[14] - Hainan Hansen Holdings holds 42.13% of the shares, making it the controlling shareholder of the company[14] Research and Development - Research and development expenses decreased by 35.92% to ¥7,867,000.00, primarily due to reduced investment in ongoing projects[9] - The company is actively involved in research and development of new products and technologies, although specific details were not disclosed in the report[15] Other Income and Expenses - Other income rose by 77.64% to ¥2,740,000.00, mainly due to government subsidies received during the reporting period[9] - Total operating costs decreased to CNY 193,715,774.24, down 4.8% from CNY 202,676,986.60 in the previous year[20] - Investment income dropped by 64.87% to ¥4,598,000.00, mainly due to decreased returns from equity method investments[9] - Investment income decreased to CNY 4,586,980.33 from CNY 13,056,492.38 in the previous year[21] Future Outlook - Future outlook includes potential market expansion and strategic acquisitions, with a focus on enhancing product offerings and market presence[15] Audit Information - The company has not undergone an audit for the first quarter report[24]